WASHINGTON, Aug. 5, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, novel anti-infectious, anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Dr. Heinz Ellerbrok to its Scientific Advisory Board.
"Dr. Ellerbrok's extensive expertise in applied molecular diagnostics will be a great asset to our infectious diseases programs and also crucial to our building novel electronic detection system and personalized diagnostics," said Dorothy H. Bray, Ph.D., Director, President and CEO, ImmunoClin Corporation.
Dr. Ellerbrok is the deputy head of the Centre for Biological Safety, Robert Koch Institute (RKI) in Germany, one of Europe's central institutions responsible for disease control and prevention. RKI is therefore the central reference institution for both applied and response-orientated research as well as for the Public Health Sector in Germany. Dr. Ellerbrok has long-standing experience in virology, including development and application of molecular diagnostics as well as applied and basic research on various pathogens, molecular biology and management of national and international research networks.
"RKI has collaborated with ImmunoClin in the European Framework Program, and I look forward to contributing to the Company's research efforts to advance cutting-edge discoveries in treating and diagnosing infections," stated Dr. Ellerbrok.
About ImmunoClin Corporation
ImmunoClin Corporation is a United States healthcare company with principal office in Washington DC, European headquarters in London, United Kingdom and laboratories in central Paris, France. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Dr. Dorothy Bray, Director, President & CEO
J. Scott Munro, CFO
Cell: +1 778-987-4308